2025/26年LP.8.1疫苗对COVID-19有效性中期估计:加拿大SPSN监测网络
加拿大SPSN网络在2025年10月26日至2026年3月7日期间,对≥12岁急性呼吸道疾病门诊患者开展检测阴性设计研究,纳入3802人(310例COVID-19病例、3492例对照)。接种疫苗后中位9周,LP.8.1疫苗对社区COVID-19的有效性为48%(95%CI:21至66),12-64岁为44%(95%CI:-12至72),≥65岁为53%(95%CI:21至73)。针对XFG变异株有效性为63%(95%CI:30至80)。
要点
- 2025/26年LP.8.1疫苗对需就医COVID-19风险约减半,总体VE为48%。
- ≥65岁人群VE为53%,敏感性分析中结果稳定。
- 针对XFG变异株VE为63%,高于测序失败病毒的26%。
核心结论
- 2025/26年LP.8.1疫苗大约将需就医的COVID-19风险减半,总体VE为48%(95%CI:21至66)。
研究设计与样本
- 加拿大SPSN网络开展检测阴性设计研究,纳入2025年10月26日至2026年3月7日期间≥12岁急性呼吸道疾病门诊患者共3802人。
- COVID-19疫苗接种信息来自登记系统,主分析排除流感病毒感染的对照。
- 敏感性分析探索纳入和/或排除COVID-19病例和/或对照中的流感及其他呼吸道病毒感染,全基因组测序支持VE解读和变异株特异性估计。
主要发现
- 共纳入3802名参与者,其中2832人(74%)为12-64岁,970人(26%)为≥65岁;COVID-19病例310例(29例接种疫苗,占9%),对照3492例(577例接种疫苗,占17%)。
- 接种后中位9周,LP.8.1总体VE为48%(95%CI:21至66);12-64岁VE为44%(95%CI:-12至72),≥65岁VE为53%(95%CI:21至73)。
- 敏感性分析中≥65岁人群VE稳定;12-64岁人群纳入流感病毒感染对照时VE下降,排除共感染时VE上升,但样本量减少存在不确定性。
- 针对测序失败与测序成功病毒的VE分别为26%(95%CI:-63至66)与53%(95%CI:24至71),针对XFG变异株VE为63%(95%CI:30至80)。
- 大多数SARS-CoV-2共感染(含测序失败者)半定量显示非SARS-CoV-2感染病毒载量更高。
关键数值与推荐
- LP.8.1疫苗总体VE为48%(95%CI:21至66),12-64岁为44%(95%CI:-12至72),≥65岁为53%(95%CI:21至73)。
- 针对XFG变异株VE为63%(95%CI:30至80),针对测序失败病毒VE为26%(95%CI:-63至66)。
- 接种后至VE评估的中位时间为9周。
临床怎么用
- 2025/26年LP.8.1疫苗可将需就医COVID-19风险约减半,支持在≥12岁人群中继续接种。
- 多重呼吸道病毒检测识别病例中的原发共感染或对照中疫苗可预防的相关感染,有助于纠正VE低估。
- 解读VE时应考虑流感及其他呼吸道病毒共循环对检测阴性设计估计的影响。
局限性
- 12-64岁人群敏感性分析中样本量减少带来不确定性,VE估计随对照和共感染处理方式波动。
- 测序失败病毒的VE估计置信区间宽且跨越无效线,变异株特异性结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUNDThe Canadian Sentinel Practitioner Surveillance Network routinely undertakes multiplex respiratory virus testing, vaccine effectiveness (VE) estimation by test-negative design (TND), and whole genome sequencing (WGS) of vaccine-targeted viruses.AIMTo estimate 2025/26 LP.8.1 VE against community-based COVID-19, including variant-specific, and explore the impact of other respiratory viruses among COVID-19 cases and/or controls.METHODSParticipants were ≥ 12-year-old outpatients presenting with acute respiratory illness between 26 October 2025 and 07 March 2026. COVID-19 vaccination information was registry-based. Primary TND analyses excluded influenza virus-infected controls. Sensitivity analyses explored inclusion and/or exclusion of influenza and other respiratory viral infections among COVID-19 cases and/or controls. WGS supported VE interpretation and variant-specific estimation.RESULTSWe included 3,802 participants (2,832 (74%) aged 12-64 years; 970 (26%) aged ≥ 65 years), with 310 COVID-19 cases (29 vaccinated; 9%) and 3,492 controls (577 vaccinated; 17%). At median 9 weeks post-vaccination, LP.8.1 VE was 48% (95%CI: 21 to 66): 44% (95%CI: -12 to 72) for 12-64 and 53% (95%CI: 21 to 73) for ≥ 65-year-olds. In sensitivity analyses, VE was stable for ≥ 65-year-olds. Among 12-64-year-olds, VE decreased when including influenza virus infections among controls but increased when excluding co-infections, recognising uncertainty with reduced sample size. Against viruses that failed vs succeeded WGS, VE was 26% (95%CI: -63 to 66) vs 53% (95%CI: 24 to 71), 63% (95%CI: 30 to 80) against the XFG variant. Most SARS-CoV-2 co-infections with semi-quantification, including those failing WGS, showed higher viral load for the non-SARS-CoV-2 infection.CONCLUSIONThe 2025/26 LP.8.1 vaccine approximately halved the medically attended COVID-19 risk. Multiplex testing to identify primary co-infections among cases, or correlated vaccine-preventable infections among controls, may address VE under-estimation.
引用
- Skowronski DM, Zhan Y, Kaweski SE, et al. Interim 2025/26 LP.8.1 vaccine effectiveness estimates against COVID-19 from the Canadian Sentinel Practitioner Surveillance Network (SPSN): insights into possible impact of influenza and other respiratory virus co-circulation. Euro Surveill. 2026. PMID: 42141877. doi:10.2807/1560-7917.ES.2026.31.18.2600331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。